Effect of tumor location and lymph node involvement on prognosis and survival in gastric cancer patients

Yıl 2020, Cilt: 6 Sayı: 2, 248 - 257, 30.08.2020

Cihan Gökler , Oktay İrkorucu , Enver Reyhan , Hilmi Bozkurt , Mustafa Görür

https://doi.org/10.30569/adiyamansaglik.717688

Öz

Aim: The present study evaluates the effect of tumor localization and lymph node involvement on prognosis and survival in patients undergoing surgery for gastric cancer.
Materials and Methods: The clinical and histopathological characteristics of patients who underwent surgery in our clinic were evaluated to determine the prognostic factors.
Results: No difference was observed in the survival rates of the groups in terms of tumor locations and metastatic lymph nodes (Log Rank p=0.255 and 0.188). A significant difference was found in the survival rates of the groups based on stage and age over 60 years (p=0.001, p=0.003). The number of metastatic lymph nodes dissected was high in gastric cancers located in the upper-third of the stomach (p=0.026, 0.036).
Conclusion: No effect of tumor localization or lymph node involvement was determined on survival in patients with gastric cancer; however, age over 60 years and stage III were found to be poor prognostic factors.

Anahtar Kelimeler

Gastric Cancer , Gastrectomy , Metastatic Lymph Nodes , Advanced Age , Prognosis

Mide kanseri hastalarında tümör lokalizasyonu ve lenf nodu tutulumunun prognoz ve sağkalıma etkisi

Öz

Amaç: Mide kanseri nedeniyle ameliyat edilen hastalarda tümör yerleşimi ve lenf nodu tutulumunun prognoz ve sağkalım üzerine etkisini değerlendirmeyi amaçladık.
Gereç ve Yöntem: Prognostik faktörleri belirlemek için kliniğimizde ameliyat edilen hastaların klinik ve histopatolojik özelliklerini araştırdık.
Bulgular: Tümör lokalizasyon grupları arasında ve metastatik lenf noduna göre sağkalım farkı gözlenmedi (Log Rank p=0,255 ve 0,188). Evreye ve 60 yaş üstü olma durumuna göre anlamlı sürvi farkı vardı (p=0,001, p=0,003). Üst 1/3 yerleşimli gastrik kanserde diseke edilen metastatik lenf nodu sayısı fazlaydı (p=0,026, 0,036)
Sonuç: Mide kanseri hastalarında tümör lokalizasyonu ve lenf nodu tutulumunun sürviye etkisi saptanmamışken, 60 yaş üzeri olma ve Evre-III kötü prognostik faktörler olarak saptandı.

Anahtar Kelimeler

Mide Kanseri , Gastrektomi , Metastatik Lenf Nodu , İleri yaş , Prognoz

Destekleyen Kurum

Herhangi bir kurum desteği yoktur

Teşekkür

Adana Şehir Hastanesi Genel Cerrahi kliniğine teşekkür ederiz.

Kaynakça

• 1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer journal for clinicians 2015; 65(2): 87-108.
• 2.Sencan I, Ince GN ed. Turkish Ministry of Health Public Health Agency Cancer Statistics. 2016; 1-60.
• 3.Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449-61.
• 4.Sert OZ, Bozkurt H, Bulut IC, et al.C-Reactive Protein to Albumin Ratio:A Reliable Marker in Gastric Surgery. Indian J Surg. (2020) https://doi.org/10.1007/s12262-020-02310-y.
• 5.Park JC, Lee YC, Kim JH, et al. Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol. 2009;99(7):395‐401.
• 6.Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer. 1998 ;1(2):125-133.
• 7.Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. 2010. CA Cancer J Clin. 2010;60:277–300.
• 8.Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14(2):317-28.
• 9.Sert OZ, Bozkurt H, Ozlem T, et al. Clinical research Clinicopathologic and immunohistochemical features of gastrointestinal stromal tumors: a single-center experience. Arch Med Sci Civil Dis. 2020; 5: 8–13.
• 10.Seevaratnam R, Bocicariu A, Cardoso R, et al. How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer. 2012 ; 15(1): 70-88.
• 11.Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010 May;11(5):439-49.
• 12.Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453‐462.
• 13.Seevaratnam R, Bocicariu A, Cardoso R, et al. A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer. 2012 ;15(1):60-9.
• 14.Liu X, Cai H, Wang Y. Prognostic significance of tumor markers in T4a gastric cancer. World J Surg Oncol. 2012;10:68.
• 15.Shim JH, Song KY, Jeon HM, et al. Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis. Ann Surg Oncol. 2014;21(7):2332‐2339.
• 16.Qiu MZ, Wang ZQ, Zhang DS, et al. Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China. Tumour Biol. 2011;32(3):509‐514.
• 17.Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439‐449.
• 18.Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9-10):1522‐1530.
• 19.Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22(14):2767‐2773.
• 20.Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer. 2011;14(2):97‐100.
• 21.Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113‐123.
• 22.Ozer I, Bostanci EB, Koc U, et al. Surgical treatment for gastric cancer in Turkish patients over age 70: early postoperative results and risk factors for mortality. Langenbecks Arch Surg. 2010;395(8):1101‐1106.
• 23.Zhou CJ, Chen FF, Zhuang CL, et al. Feasibility of radical gastrectomy for elderly patients with gastric cancer. Eur J Surg Oncol. 2016;42(2):303‐311.
• 24.Oñate-Ocaña LF, Aiello-Crocifoglio V, Gallardo-Rincón D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381‐389.
• 25.Tegels JJ, De Maat MF, Hulsewé KW, Hoofwijk AG, Stoot JH. Improving the outcomes in gastric cancer surgery. World J Gastroenterol. 2014;20(38):13692‐13704.
• 26.Shim H, Cheong JH, Lee KY, Lee H, Lee JG, Noh SH. Perioperative nutritional status changes in gastrointestinal cancer patients. Yonsei Med J. 2013;54(6):1370‐1376.
• 27.Rey-Ferro M, Castaño R, Orozco O, Serna A, Moreno A. Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition. 1997;13(10):878‐881.
• 28.Weimann A, Braga M, Harsanyi L, et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr. 2006;25(2):224‐244.
• 29.Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20(2):217‐225.